News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dynavax Technologies Corporation (DVAX) Ends Development Of Allergy Drug Tolamba After Trial Failure



5/16/2008 7:27:37 AM

AP -- Dynavax Technologies Corp. Friday said that it is ending development of its ragweed allergy drug Tolamba after it failed a midstage trial. The drug developer said that it the drug did not show a significant improvement over placebo in reducing nasal symptoms.

Read at BioSpace.com
Read at AP
Read at Reuters


comments powered by Disqus
BioSpace.com
AP
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES